Two people in Denmark suffered cerebral hemorrhages after receiving the COVID-19 vaccine from AstraZeneca, according to several reports.
Two hospital staff members received the vaccine less than 14 days before suffering cerebral hemorrhages, Reuters reported. The Danish Medicines Agency confirmed that it had received two “serious reports”, but did not give further details on the matter.
The New York Times reported that one of the patients died and the other, a woman in her 30s, is very ill.
The Hill has contacted AstraZeneca to comment.
The reports are the latest in a series of media reports about a small number of people suffering from blood clots after being shot from the AstraZeneca vaccine. The news also represents the second death in Denmark after the administration of the British-Swedish company’s vaccine.
Denmark stopped use of the vaccine on March 11 after a 60-year-old woman died due to a blood clot after the shot. Other countries, including Germany, France, Italy, Spain, Ireland and Norway, have also blocked its use.
The vaccine has not yet been authorized by the U.S. Food and Drug Administration.
AstraZeneca he said last Sunday that there was no evidence linking the vaccine to blood clots after reviewing 17 million features administered throughout Europe.
The European Medicines Agency, the European Union’s drug regulator, he said Thursday that the AstraZeneca vaccine is safe and effective to use, but did not rule out a link to blood clots. The agency said it would add a warning to the product about the possibility of the side effect.
Reuters noted that some countries have reversed their decisions amid the EMA announcement.
The World Health Organization has recommended that countries continue to use the vaccine, saying the benefits of the vaccine outweigh its risks.